Edison Investment Research - BC Iron (BCI) BCI Minerals - All on course

Report

Edison Investment Research

Alison Turner

BCI Minerals - All on course

In its September quarterly report, BCI reported that the definitive feasibility study (DFS) on the Mardie salt and potash project was 75% complete as at end-September 2019, with the expectation that it will be completed in Q1 CY20. In the meantime, the company is embarking on construction of a large-scale trial pond programme to test the envisaged materials and methods of construction and thereby substantially mitigate future construction risk.

30/10/2019 7 EN

Underlying

BC Iron

BC Minerals is engaged in operation, development and exploration of mineral projects, focusing primarily on iron ore deposits in the Pilbara region of Western Australia.

See profile

AU000000BCI0 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Alison Turner

Other Reports on these Companies

MarketLine

Mount Gibson Iron Ltd - Company Profile and SWOT Analysis

Summary Mount Gibson Iron Ltd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Mount Gibson Iron Ltd (Mount Gibson) is a producer of iron ore in Australia. The company is involved in the mining, exploration, and development of iron ore deposits in Australia. It operates Extension Hill hematite project in the Mt Gibson ranges, southeast of Geraldton. The company through its...

EUR 164.55

December 30, 2023 December 30, 2023 1 EN

MarketLine

Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances

Summary Marketline's Argosy Minerals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity un...

EUR 329.11

August 28, 2023 August 28, 2023 1 EN

Edison Investment Research

BCI Minerals - Termination of coverage

Edison Investment Research is terminating coverage on BCI Minerals (BCI) and Sunesis Pharmaceuticals (SNSS). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

September 29, 2020 September 29, 2020 1 EN

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

18h / 42m 18h / 42m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

18h / 54m 18h / 54m 1 EN

Martyn King

Martyn King

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

19h / 12m 19h / 12m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BCI Minerals - All on course

Mount Gibson Iron Ltd - Company Profile and SWOT Analysis

Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances

BCI Minerals - Termination of coverage

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Foxtons Group - FY24 underpinned by market share gains

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe